Nautilus Biotechnolgy financials
$1.37+22.97%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $175.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 92.1% | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$15.8M | -$16.1M | -$15.4M | -$15.5M | -$17.1M | -$18.8M | -$20.0M | -$19.1M | -$20.8M | -$21.6M | -$20.0M | -$19.1M |
| Net income | -$14.5M | -$14.7M | -$13.8M | -$13.6M | -$15.0M | -$16.6M | -$17.6M | -$16.4M | -$18.0M | -$18.7M | -$17.0M | -$15.9M |
| Net margin | −7615.3% | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.11 | $-0.12 | $-0.11 | $-0.11 | $-0.12 | $-0.13 | $-0.14 | $-0.13 | $-0.14 | $-0.15 | $-0.14 | $-0.13 |
| EBITDA | -$15.5M | -$15.8M | -$15.0M | -$15.0M | -$16.6M | -$18.4M | -$19.5M | -$18.6M | -$20.3M | -$21.1M | -$19.4M | -$18.6M |
| Operating cash flow | -$13.7M | -$13.1M | -$12.4M | -$11.0M | -$13.3M | -$13.9M | -$14.3M | -$13.1M | -$15.5M | -$16.3M | -$13.9M | -$11.7M |
| Free cash flow | -$14.2M | -$13.6M | -$12.6M | -$11.5M | -$13.7M | -$14.2M | -$14.6M | -$13.8M | -$16.0M | -$16.9M | -$14.3M | -$12.6M |
| Diluted shares | 127.1M | 126.6M | 126.4M | 126.3M | 126.2M | 126.1M | 125.8M | 125.5M | 125.3M | 125.1M | 125.5M | 124.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.2M | $14.6M | $12.4M | $23.9M | $34.5M | $33.2M |
| Short-term investments | $70.9M | $81.2M | $91.0M | $107.6M | $113.4M | $105.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $163.6M | $177.8M | $191.1M | $200.9M | $213.2M | $227.7M |
| Total liabilities | $32.5M | $33.4M | $34.1M | $31.8M | $32.1M | $33.3M |
| Shareholders' equity | $131.1M | $144.4M | $157.0M | $169.1M | $181.1M | $194.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology